We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rabbit Poxvirus Kills Brain Cancer Cells

By Biotechdaily staff writers
Posted on 07 Dec 2005
Researchers have used myxoma virus, a poxvirus that causes fatal myxomatosis in rabbits, to kill human brain cancer cells both in tissue culture and after transplantation into mice.

After earlier studies showed that the mxyoma virus could survive in a variety of human tumor cells in culture, investigators at the University of Western Ontario (London, Canada) and the University of Calgary (Alberta, Canada) performed a series of experiments designed to test its effectiveness against a human malignant brain cancer (glioma).

They reported in the November 1, 2005, issue of Cancer Research that when used to infect eight different glioma cell lines growing in tissue culture, the myxoma virus reproduced in seven of the lines and killed the cells.

In another series of experiments, a mouse model was created by transplantation of human glioma cells into the animals' brains. More...
The growing tumors were then treated by being inoculated with either live myxoma virus or with myxoma virus that had been inactivated by exposure to ultraviolet (UV) light. All the animals treated with UV inactivated virus were dead after about 50 days, while 92% of those treated with the live virus were still living when the experiment was ended after 130 days. The virus itself had no apparent toxic effects on the mice.
"Those animals continued to show a selective and long-lived myxoma virus infection in the tumors themselves but that infection did not spread and harm the animal,” explained senior author Dr. Peter Forsyth, professor of oncology, biochemistry, and molecular biology at the University of Calgary. "This and other factors suggest that myxoma virus warrants further investigation as a potential treatment for malignant brain tumors in people.”




Related Links:
University of Western Ontario
University of Calgary

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.